Renaissance Technologies (RenTech)'s AUTL Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 2.3 M shares of Autolus Therapeutics plc (AUTL) worth $3.17 M, representing 0.00% of the portfolio. First purchased in 2019-Q2, this long-term strategic position has been held for 25 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in AUTL, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2025, adding 3.13 M shares. Largest reduction occurred in Q4 2025, reducing 1.78 M shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Autolus Therapeutics plc (AUTL) Holding Value Over Time
Track share changes against reported price movement
Quarterly Autolus Therapeutics plc (AUTL) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -805,905 | Reduce 25.95% | 2.3 M | $1.38 |
| Q4 2025 | -1.78 M | Reduce 36.38% | 3.11 M | $1.99 |
| Q3 2025 | +3.13 M | Add 178.74% | 4.88 M | $1.63 |
| Q2 2025 | +167,075 | Add 10.55% | 1.75 M | $2.28 |
| Q1 2025 | +965,183 | Add 155.94% | 1.58 M | $1.55 |
| Q4 2024 | +368,071 | Add 146.72% | 618,942 | $2.35 |
| Q3 2024 | -894,185 | Reduce 78.09% | 250,871 | $3.63 |
| Q2 2024 | +821,156 | Add 253.52% | 1.15 M | $3.48 |
| Q1 2024 | +164,300 | Add 102.94% | 323,900 | $6.38 |
| Q4 2023 | -114,079 | Reduce 41.68% | 159,600 | $6.44 |
| Q3 2023 | +122,479 | Add 81.00% | 273,679 | $2.33 |
| Q2 2023 | +42,800 | Add 39.48% | 151,200 | $0.00 |
| Q1 2023 | +62,100 | Add 134.13% | 108,400 | $0.00 |
| Q4 2022 | +21,100 | Add 83.73% | 46,300 | $0.00 |
| Q3 2022 | +12,400 | Add 96.88% | 25,200 | $2.14 |
| Q2 2022 | +12,800 | New Buy | 12,800 | $2.81 |
| Q2 2021 | -81,588 | Sold Out | 0 | $0.00 |
| Q1 2021 | +632 | Add 0.78% | 81,588 | $5.72 |
| Q4 2020 | +27,300 | Add 50.88% | 80,956 | $8.94 |
| Q3 2020 | -18,744 | Reduce 25.89% | 53,656 | $11.65 |
| Q2 2020 | -88,096 | Reduce 54.89% | 72,400 | $16.04 |
| Q1 2020 | +119,796 | Add 294.34% | 160,496 | $5.99 |
| Q4 2019 | -8,300 | Reduce 16.94% | 40,700 | $13.19 |
| Q3 2019 | -41,096 | Reduce 45.61% | 49,000 | $12.43 |
| Q2 2019 | +90,096 | New Buy | 90,096 | $16.11 |
Renaissance Technologies (RenTech)'s Autolus Therapeutics plc Investment FAQs
Renaissance Technologies (RenTech) first purchased Autolus Therapeutics plc (AUTL) in Q2 2019, acquiring 90,096 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Autolus Therapeutics plc (AUTL) for 25 quarters since Q2 2019.
Renaissance Technologies (RenTech)'s largest addition to Autolus Therapeutics plc (AUTL) was in Q3 2025, adding 4,881,372 shares worth $7.96 M.
According to the latest 13F filing for Q1 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 2,299,499 shares of Autolus Therapeutics plc (AUTL), valued at approximately $3.17 M.
As of the Q1 2026 filing, Autolus Therapeutics plc (AUTL) represents approximately 0.00% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Autolus Therapeutics plc (AUTL) was 4,881,372 shares, as reported at the end of Q3 2025.